Goldman Sachs’s EnteroMedics Inc. ETRM Stock Holding History

Goldman Sachs’s Portfolio ETRM Stock Details ETRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-203	Closed	-$262K	–	7648
2014 Q3	$262K	Sell	203 -10	-5%	-$14.7K	﹤0.01%	5889
2014 Q2	$348K	Sell	213 -154	-42%	-$288K	﹤0.01%	5662
2014 Q1	$701K	Sell	367 -49	-12%	-$116K	﹤0.01%	4984
2013 Q4	$891K	Buy	+416	New	+$670K	﹤0.01%	4837

Other funds holding ETRM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Goldman Sachs's ETRM Position: Q4 2016 in Review

Goldman Sachs sold out of EnteroMedics Inc. (ETRM) in Q4 2016, closing a stake of 459 shares — an estimated $4K sold.

Goldman Sachs first reported a position in ETRM in Q1 2014 and held it in 8 quarters. The position peaked at $119K in Q3 2014. 18 funds tracked by Wall St. Rank hold ETRM as of Q4 2016.

Goldman Sachs reported no remaining EnteroMedics Inc. position as of Q4 2016 after selling out during the quarter.
Goldman Sachs sold 459 EnteroMedics Inc. shares in Q4 2016, an estimated $4K.
Goldman Sachs first reported a position in EnteroMedics Inc. in Q1 2014 and held it in 8 quarters.
Goldman Sachs's EnteroMedics Inc. position peaked at $119K in Q3 2014.
18 funds tracked by Wall St. Rank held EnteroMedics Inc. as of Q4 2016.

Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.